Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRKL siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intranasal, Parenteral
01
Overview
CRKL siRNA is a research-grade small interfering RNA (siRNA) molecule designed to silence the expression of the CRKL gene, which encodes the CRK-like adaptor protein. CRKL is an adaptor protein involved in various signaling pathways, including those downstream of ALK and BCR-ABL, and is often overexpressed in multiple malignancies. By utilizing the RNA interference (RNAi) pathway, CRKL siRNA induces the degradation of CRKL mRNA, leading to reduced protein levels. In preclinical research, this knockdown has been shown to inhibit cell proliferation, migration, and invasion, and to reverse chemotherapy resistance in models of glioblastoma, non-small cell lung cancer, gastric cancer, and leukemia. It is primarily used as a laboratory tool to validate CRKL as a therapeutic target and is not currently a clinical-stage drug candidate.
- Other names
- CRKL small interfering RNAsiRNA targeting CRKL
02
Targets
CRKL (CRK-like proto-oncogene, adaptor protein)
Beyond the preview
Go deeper on CRKL siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRKL siRNA.